When a company's share price is faltering but they strongly believe in their technology, the key employees and the Board of Directors buy serious amounts of shares on the open market.
This builds shareholder's confidence but more importantly can grow the share price. Brokers and investors see the CEO and BOD buying a couple of million shares each on the open market and they start accumulating shares in this company.
We have a couple of longs who post on here who strongly believe in this CEO and the direction of this company.
One of them predicts that the share price will reach $2.00 by the end of the year.
Why not put all of your money in and buy more shares on the open market?
You will grow it by over ten times by the end of the year!!!!!
Just my opinion
because the price is too high, i do believe the insiders will buy up shares, but not until the price is right, it certainly wont be above the pipe price, maybe .03-.05 cents would be there buying price
Parent wrote "Yes, warfield, I will do exactly that especially since I project the PPS to be 2 dollars before year's end. Thanks
It's at 14 cents and in 6 months what news exactly are you projecting is going happen before 2014 ? Just pulling a number out of your back side ?
Parents ..... such a bold prediction. This stock is near death it appears. Nanologix can't seem to hold key employees, will not divulge financials, will not announce sales figures yet you predict two dollars a share. You must take us for fools as you slowly sell your position. LOL .... in my opinion.
I wonder if people who said wonderful things are buying like crazy ? I mean look at what they said ? How could they say those things and not buy hand over fist all trading day long ?
Dr. Allan Katz, M.D., professor and Vice-Chairman of Obstetrics and Gynecology at the University of Texas Medical School in Houston, and chief of Gynecology at Hermann Memorial Hospital in Houston stated, "We have relied far too long on traditional culture based technology, and this practice has undoubtedly contributed towards the development of microbial resistance. The technology offered by NanoLogix is exciting as it promises more rapid results in a time when it most matters to the patient. It also holds vast potential as the technology extends beyond GBS and MRSA and tests can be performed by almost anyone, in any corner of the world."
Dr. Sebastian Faro, M.D., Chief of Obstetrics and Gynecology at LBJ Hospital in Houston, Texas, said, "This is an extremely exciting time to be working on the development of diagnostic tests to identify pathogenic bacteria in a rapid manner. This technology from NanoLogix will revolutionize the process of identifying disease causing bacteria and facilitate a more direct approach in choosing appropriate antibiotic therapy."
You know Warfield, that's right.
In all the years invested here I have never seen anything from the SEC that shows where the principal officers have invested in "retail" shares. Not the CEO, the BOD, no pumper PIPES, it appears that none are willing to take that level of risk, in a company they seem to BELIEVE very strongly in. Iv'e seen it in other Pinks, but not here.
The reason you've never seen an SEC filing by the executive branch is because nanologix isn't an SEC registered company. You only file such documents, including trade transactions, if ours registered with the SEC. All pink sheets, with the exception of foreign ADR's that trade on the pink sheets, are not registered with the SEC.
It's not just Press Releases, there are updates with stuff like this below, if they believe so much about capturing a SIGNIFICANT PORTION of that market. Surely they would all be buying like no tomorrow, right ?
Global in Vitro diagnostic is currently estimated to have an annual value of $44 billion USD
NanoLogix’s management is focused on positioning our BNP and BNF technology to enter and capture a significant portion of that market. We believe that businesses, and indeed whole industries, that need or supply diagnostics will choose our faster, simpler and cheaper technology over expensive, highly complex equipment that cannot differentiate between live active-threat and dead bacteria.